retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports What GLP‑3 Really Is: Retatrutide

Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus

Diabetes (Type 2) Available in NZ = Dulaglutide (Trulicity, weekly injection) or Liraglutide (Victoza, daily injection)

Given the clinical evidence reviewed above, patients with type 2 diabetes and/or obesity are the most promising candidate population to benefit from GLP-1RA-centered pharmacotherapy to improve cardiovascular and kidney outcomes

The ease of use, great efficacy, and improvement in cardiovascular outcomes seen with GLP-1 RAs are reflected in their exponential use trend, with the growth rates reaching as high as 80% to more than 100% per month for commonly used formulations [4]

The 42% to 48% CRP reductions were achieved at 1.0 to 2.4 mg semaglutide, not at 0.05 mg

The systems that matter most for dementia prevention In longevity medicine, the practical question is not whether one therapy is good for the brain. The better question is whether the persons overall biology is moving toward resilience or vulnerability